Table 2.
Depiction of Mutations and Treatment of 14 Patients with Concomitant EGFR Mutations and HER2 Amplification Who Suffered from Resistance of EGFR-TKIs
| Patient | Sex | Age | Genetic Test Pre-EGFR-TKI | Possible Pathogenic Alterations | Prior Targeted-Therapy | Treatment Lines | EGFR Alteration | HER2 Amp | Possible Resistant Alterations | Therapy | Best Response | Disease Free Survival |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | F | 47 | NGS | EGFR L858R/T790M | Osimertinib | 2nd | L858R/T790M, | + | BRCA1 amplification | Afatinib | NA | 1m |
| 2 | M | 55 | NA | EGFR L858R | Gefitinib | 2nd | L858R, | + | Afatinib+ | PR | 3m | |
| FGF3 H239Y | ACC006 | |||||||||||
| 3 | M | 51 | ARMS-EGFR | EGFR E746_A750del | Erlotinib | 1st | E746_A750del, | + | FAT1 | Afatinib | PR | 6m |
| E4000K | ||||||||||||
| 4 | F | 43 | NA | EGFR E746_A750del | Gefitinib | 2nd | E746_A750del, | + | NA | Osimertinib+Pylotinib | SD | 4m |
| 5 | M | 71 | NGS | EGFR L858R | Gefitinib | 1st | L858R, | + | CCNE1 amplification JMJD1C-HER2 | Gefitinib+Pylotinib | PR | 8m |
| 6 | F | 51 | ARMS-EGFR | EGFR E746_A750del/T790M | Erlotinib Gefitinib Osimertinib |
5th | E746_A750del, | + | ATM I1525_L1527del | Chemotherapy | PR | 4m |
| 7 | F | 50 | NGS | EGFR L858R, HER2 D277Y | Icotinib Osimertinib |
3rd | L858R | + | CCND1/CDK4/FGF19/FGF4/FGF3/IGF1R/IKBKB amplification, HER2 D277Y | Gefitinib | SD | 5m |
| 8 | F | 56 | NA | EGFR L858R | Erlotinib | 3rd | L858R | + | PTEN Q245*/Q171E | NA | NA | NA |
| 9 | F | 71 | NA | EGFR E746_A750del | Gefitinib Osimertinib |
2nd | E746_A750del/T790M/C797S | + | HOOK3-ALK, TRIM33-RET ALK/CDKN2A amplification, BRAF V600E | Brigatinib+Osimertinib+Bevacizumab | SD | 2m |
| 10 | F | 65 | NA | EGFR E746_A750del | Gefitinib Osimertinib |
2nd | E746_A750del | + | NA | NA | NA | NA |
| 11 | M | 68 | NGS | EGFR L8585R, ERBB2 S310F | Gefitinib Osimertinib |
2nd | L858R/T790M | + | PIK3CA E545K, PIK3CA/AKT2/CCNE1 amplification, ALK E1072K, RET R77C, SPEN R2624Q | NA | NA | NA |
| 12 | F | 66 | NGS | EGFT L861Q | Afatinib | 2nd | L861Q | + | CDK4 amplification | Chemotherapy | SD | 4m |
| 13 | M | 76 | NGS | EGFR L858R/T790M/E709K | Gefitinib Afatinib |
2nd | L858R/E709K | + | HER2 G776V/V777L/S653C, VEGFA amplification | Osimertinib+bevacizumab | SD | – |
| 14 | M | 71 | NGS | EGFR L858R | Gefitinib | 2nd | L858R/T790M | + | NTRK1 A463T, CCNE1 R240C, | Chemotherapy | PR | 1m |
Abbreviations: Amp, amplification; F, female; M, male; m, months; NA, not available; PR, partial reaction; SD, stable disease.